Document Detail

Effect of Naturopathic and Nutritional Supplement Treatment on Tumor Response, Control, and Recurrence in Patients with Prostate Cancer Treated with Radiation Therapy.
MedLine Citation:
PMID:  23036139     Owner:  NLM     Status:  Publisher    
Abstract Objectives: Use of naturopathic and nutritional supplements (NNS) with antioxidant activity is controversial in patients receiving radiation therapy. The effects of concomitant use of NNS with antioxidant activity during radiation therapy for prostate cancer were investigated in terms of clinical tumor responsiveness, kinetics, and durability. Materials and methods: A retrospective investigation was done of 134 patients treated with curative intent for limited-stage prostate cancer by radiation therapy. Patients self-selected to receive NNS as part of their treatment and maintenance during an extended post-treatment interval of at least 2 years. The outcome measures were the following: prostate-specific antigen (PSA) nadir; ≥24 months post-treatment PSA; time to reach nadir; and time to last follow-up were compared across +NNS and -NNS. Results: Sixty-nine (69) patients elected to receive NNS while 65 did not. Seventy-seven (77) (+NNS 39, -NNS 38) patients received hormone therapy while 57 (+NNS 30, -NNS 27) did not. In the nonhormone cohort, median pretreatment PSA, nadir, post-treatment PSA, time to reach nadir, and time to follow-up were 5.5 ng/mL, 0.56 ng/mL, 0.61 ng/mL, 25 months, and 39.7 months for the -NNS group and 5.1 ng/mL, 0.32 ng/mL, 0.44 ng/mL, 27 months, and 50.1 months for the +NNS group, respectively (p>0.05 for all). Similarly, no significant differences were observed between +NNS and -NNS in the hormone-receiving cohort. Conclusions: The clinical tumor response to radiation therapy in patients with limited-stage prostate cancer is not inhibited by concomitant NNS based on the magnitude of the PSA response, the velocity of the PSA nadir, and the duration of PSA normalization.
Donald P Braun; Digant Gupta; Timothy C Birdsall; Michele Sumner; Edgar D Staren
Related Documents :
24189279 - Expanded access study of patients with advanced basal cell carcinoma treated with the ...
24795069 - Effectiveness and safety of different azacitidine dosage regimens in patients with myel...
24070139 - The pan european emesis registry (peer): a critical appraisal of the italian experience.
23404099 - In vivo efficacy of melanoma internal radionuclide therapy with a (131) i-labelled mela...
15157659 - Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic t...
23803079 - Prediction of chemotherapeutic response in unresectable non-small-cell lung cancer (nsc...
22914439 - Targeting the apoptotic pathway in chondrosarcoma using recombinant human apo2l/trail (...
19670699 - Her2, egfr and topiia gene amplification and protein expression in synovial sarcoma bef...
8395409 - Superselective intra-arterial chemotherapy with mitomycin c in hepatic neoplasms.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-4
Journal Detail:
Title:  Journal of alternative and complementary medicine (New York, N.Y.)     Volume:  -     ISSN:  1557-7708     ISO Abbreviation:  J Altern Complement Med     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508124     Medline TA:  J Altern Complement Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Office of Clinical Research, Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center , Zion, IL.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Australasian respiratory and emergency physicians do not use the pneumonia severity index in communi...
Next Document:  Effect of risk adjustment method on comparisons of health care utilization between complementary and...